(PINK) Simplify Exchange Traded - Overview
Etf: Pharmaceuticals, Biotech, Medical Devices, Health Services
Dividends
| Dividend Yield | 0.77% |
| Yield on Cost 5y | 1.03% |
| Yield CAGR 5y | 30.69% |
| Payout Consistency | 86.9% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 20.8% |
| Relative Tail Risk | 2.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.85 |
| Alpha | 7.62 |
| Character TTM | |
|---|---|
| Beta | 0.641 |
| Beta Downside | 0.616 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.77% |
| CAGR/Max DD | 0.71 |
Description: PINK Simplify Exchange Traded January 19, 2026
Under its mandate, Simplify Health Care ETF (NYSE ARCA:PINK) allocates at least 80% of its capital-plus any investment-purpose borrowings-to U.S. health-care securities as defined by the GICS health-care sector, typically spanning 50-100 companies focused on innovative medicines and cost-efficiency business models.
Key sector drivers include the U.S. population aging (≈10% of adults will be 65+ by 2030), which historically lifts Medicare and private health-care spending at an average annual growth of 5-6%; biotech R&D intensity, measured by the industry’s average R&D spend of ~20% of revenue; and the ETF’s modest expense ratio of 0.30% with roughly $150 million in assets under management, providing a cost-effective exposure to the space.
For a deeper, data-rich view of valuation and risk metrics, consider reviewing the ETF’s profile on ValueRay.
What is the price of PINK shares?
Over the past week, the price has changed by +0.53%, over one month by -4.25%, over three months by +7.99% and over the past year by +23.08%.
Is PINK a buy, sell or hold?
What are the forecasts/targets for the PINK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 40.8 | 12.1% |
PINK Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 348.1m USD (348.1m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 348.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 348.1m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.28% (E(348.1m)/V(348.1m) * Re(8.28%) + (debt-free company))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)